procarbazine has been researched along with Heart Diseases in 9 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "By October 2008, cardiac diseases (CD) had been diagnosed in 50 of 1,132 patients aged 15." | 1.36 | Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. ( Bölling, T; Brämswig, J; Bruch, C; Dieckmann, K; Dörffel, W; Heinecke, A; Kotthoff, S; Pötter, R; Riepenhausen, M; Schellong, G; Vogt, J, 2010) |
| " It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology." | 1.35 | [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma]. ( Bozhenko, VK; Datsenko, PV; Ivashin, AV; Mel'nik, IuD; Pan'shin, GA; Podol'skiĭ, PN; Sotnikov, VM, 2009) |
| "Cardiotoxicity is a well recognized side effect of anthracyclines (doxorubicin and epirubicin) or antracenadiones (mitoxantrone) at cumulative or high doses." | 1.29 | Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. ( Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ, 1993) |
| "Although most patients with Hodgkin's disease refractory to MOPP treatment will respond to either ABVD or B-CAVe chemotherapy, subsequent long-term disease-free survival is unusual." | 1.27 | Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. ( Harker, WG; Kushlan, P; Rosenberg, SA, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Podol'skiĭ, PN | 1 |
| Datsenko, PV | 1 |
| Pan'shin, GA | 1 |
| Sotnikov, VM | 1 |
| Mel'nik, IuD | 1 |
| Ivashin, AV | 1 |
| Bozhenko, VK | 1 |
| Schellong, G | 1 |
| Riepenhausen, M | 1 |
| Bruch, C | 1 |
| Kotthoff, S | 1 |
| Vogt, J | 1 |
| Bölling, T | 1 |
| Dieckmann, K | 1 |
| Pötter, R | 1 |
| Heinecke, A | 1 |
| Brämswig, J | 1 |
| Dörffel, W | 1 |
| Elbl, L | 1 |
| Vasova, I | 1 |
| Kral, Z | 1 |
| Tomaskova, I | 1 |
| Smardova, L | 1 |
| Wagnerova, B | 1 |
| Jedlicka, F | 1 |
| Vorlicek, J | 1 |
| Diehl, V | 1 |
| Fuchs, M | 1 |
| Harker, WG | 1 |
| Kushlan, P | 1 |
| Rosenberg, SA | 1 |
| Avilés, A | 1 |
| Arévila, N | 1 |
| Díaz Maqueo, JC | 1 |
| Gómez, T | 1 |
| García, R | 1 |
| Nambo, MJ | 1 |
| Allavena, C | 1 |
| Conroy, T | 1 |
| Aletti, P | 1 |
| Bey, P | 1 |
| Lederlin, P | 1 |
| Santoro, A | 1 |
| Bonadonna, G | 1 |
| Valagussa, P | 1 |
| Zucali, R | 1 |
| Viviani, S | 1 |
| Villani, F | 1 |
| Pagnoni, AM | 1 |
| Bonfante, V | 1 |
| Musumeci, R | 1 |
| Crippa, F | 1 |
| Watchie, J | 1 |
| Coleman, CN | 1 |
| Raffin, TA | 1 |
| Cox, RS | 1 |
| Raubitschek, AA | 1 |
| Fahey, T | 1 |
| Hoppe, RT | 1 |
| Van Kessel, A | 1 |
1 review available for procarbazine and Heart Diseases
| Article | Year |
|---|---|
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 2007 |
1 trial available for procarbazine and Heart Diseases
| Article | Year |
|---|---|
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined | 1987 |
7 other studies available for procarbazine and Heart Diseases
| Article | Year |
|---|---|
[Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Heart; | 2009 |
Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2010 |
Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; D | 2006 |
Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1984 |
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Female; Follow-Up St | 1993 |
Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Exerci | 1992 |
Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Composition; Elec | 1987 |